Zetagen Therapeutics Announces Successful Completion of Enrollment in Phase IIa Clinical Study of ZetaMet^™ (Zeta-BC-003) Metastatic Breast Cancer

Zetagen Therapeutics, Inc. announced they have successfully completed enrollment in their Phase IIa study, which will evaluate ZetaMet^™ (Zeta-BC-003) in the treatment of spinal metastatic lytic breast cancer lesions.